Eager Investors Snap Up Indian IPOs On Positive Health Care Outlook
This article was originally published in PharmAsia News
Investors upbeat about the prospects for India's health care sector have given a strong welcome to IPOs by Alkem Laboratories, the country's fifth-largest drug company in terms of domestic revenues, and Dr. Lal PathLabs which has a strong nationwide presence, as the overall first-time share sale market regains its vigor to post its best performance in five years.
You may also be interested in...
Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.